ODE IV Deputy Director Cox Will Emphasize Antimicrobial Drug Development
FDA Division of Special Pathogen & Immunologic Drug Products Medical Team Leader Edward Cox, MD, plans to continue to focus on development of antimicrobial drugs that target resistant pathogens following his appointment as FDA's Office of Drug Evaluation IV deputy director
You may also be interested in...
Companies seeking an indication for an antimicrobial agent to treat resistant pathogens could rely mostly on pharmacokinetic and pharmacodynamic studies, FDA said
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials